News Briefing channel feed

Blue­bird sends blood dis­or­der drug to FDA for ap­proval; CG On­col­o­gy en­ters col­lab­o­ra­tion with Roche for Tecen­triq

4 years ago

Take­da snaps up the Japan­ese rights to an old Shire cast-off; Boehringer In­gel­heim ac­quires Abexxa Bi­o­log­ics

4 years ago

Den­mark's Gubra to col­lab­o­rate with Bay­er on pep­tides; Sam­sung and Bio­gen re­ceive FDA ap­proval for Lu­cen­tis biosim­i­lar

4 years ago

Philip Mor­ris gets share­hold­er back­ing in Vec­tura saga; Tarve­da strikes ex­clu­sive li­cens­ing agree­ment with Sci­Clone

4 years ago

FDA ac­cepts In­tel­li­a's IND for CRISPR and TCR-T cell ther­a­py; San­té clos­es Fund IV at $260M

4 years ago

Three De­mo­c­rat reps op­pose Medicare drug pric­ing plan; Alpine Im­mune an­nounces pri­vate place­ment

4 years ago

Ab­Cellera ac­quires trans­mem­brane pro­tein pro­duc­er; Com­pass gains psy­che­del­ic IP port­fo­lio

4 years ago

Ger­man ra­dio­phar­ma forms an­oth­er Chi­na joint ven­ture; Urovan­t's Gemte­sa pass­es blood pres­sure study

4 years ago

Canada's Bausch to pay $300M in an­titrust set­tle­ment; Cardiff re­leas­es da­ta on mCRC tri­al

4 years ago

Roche to buy up di­ag­nos­tics part­ner TIB Mol­bi­ol; PAQ to part­ner with In­sil­i­co

4 years ago

Look­ing for fresh start fol­low­ing a Duchenne dis­as­ter, Cataba­sis re­brands; Huadong and In­sil­i­co team up in on­col­o­gy

4 years ago

Vac­citech makes short move to new head­quar­ters; En­ter­o­Bi­otix rais­es more than $21M in Se­ries A

4 years ago

Bris­tol My­ers li­cens­es for Evotec mol­e­cule for $20M; FDA ap­proves Im­pel's mi­graine nasal spray Trud­he­sa

4 years ago

In­novent and Gen­Fleet reach deal for KRAS in­hibitor; TCR2 re­ceives FDA's ODD on ga­vo-cel

4 years ago

Lig­and Phar­ma part­ner wins Chi­nese ap­proval for an­ti-PD-1; Brick­ell re­ceives ex­clu­sive rights to DYRK1A in­hibitor

4 years ago

SR One leads $55M round for nasal al­ter­na­tive to EpiPen; Sanofi pulls web­site over ac­cu­ra­cy con­cerns

4 years ago

Spring­Works teams with Dana-Far­ber to test BC­MA com­bo; VBL restarts PhI­II tri­al af­ter FDA clears gene ther­a­py batch­es

4 years ago

EC ap­proves Bio­Marin drug as first treat­ment for chil­dren with com­mon form of dwarfism; Servi­er sN­DA wins ap­proval

4 years ago

Am­neal touts re­sults from Phase III tri­al in Parkin­son's; No­vaRock part­ners on can­cer drug

4 years ago

Chi­nese phar­ma groups part­ner in $150M li­cens­ing deal; Pfiz­er to join law­suit on tar­iffs

4 years ago

Im­muno­core's bis­pe­cif­ic lands speedy re­view with FDA, EMA; Low-pro­file gene ther­a­py play­er grabs $30M

4 years ago

KalVista clears in­ter­na­tion­al reg­u­la­to­ry hur­dles on HAE tri­al; Elix­iron rais­es $27M in Se­ries A

4 years ago

In­sil­i­co finds a new part­ner for AI drug dis­cov­ery; EU launch­es Il­lu­mi­na probe af­ter Grail merg­er close

4 years ago

Philip Mor­ris nabs over 20% of Vec­tura's shares; On­copep­tides drug may be head­ed for ad­comm, CEO says

4 years ago
First page Previous page 27282930313233 Next page Last page
A service from the Financial Times